Hepatitis C tests continue after NH tech’s arrest






CONCORD, N.H. (AP) — Hospitals across the country recommended hepatitis C testing for about 7,900 patients last summer after a traveling medical worker was accused of stealing drugs and infecting patients with tainted syringes in New Hampshire. But five months later, nearly half of those who were possibly exposed to the liver-destroying disease in other states have yet to be tested.


Described by prosecutors as a “serial infector,” David Kwiatkowski is accused of stealing syringes of the powerful painkiller fentanyl from the cardiac catheterization lab at New Hampshire’s Exeter Hospital and replacing them with saline-filled syringes tainted with his own blood. In jail since his arrest in July, he pleaded not guilty to 14 federal drug charges earlier this month and is expected to go to trial next fall.






Before April 2001, when he was hired in New Hampshire, Kwiatkowski worked as a traveling cardiac technologist in 18 hospitals in seven states, moving from job to job — despite being fired twice over allegations of drug use and theft.


Thirty-two people in New Hampshire have been diagnosed with the same strain of hepatitis C that Kwiatkowski carries, along with six in Kansas, five in Maryland and one in Pennsylvania. At least 3,700 people outside New Hampshire have yet to be tested, hospitals and public health officials told The Associated Press.


For example, in Michigan, where Kwiatkowski grew up and started his career, about 2,300 patients at five hospitals were notified that they may have been exposed to hepatitis C by Kwiatkowski. As of early December, only about 500 had gone in for testing, none of whom were diagnosed with a strain linked to the New Hampshire outbreak, according to the Michigan Department of Community Health.


In Pennsylvania, 2,280 patients at the University of Pittsburgh Medical Center Presbyterian were notified that they should get tested, but only 840 have, one of whom was diagnosed with a matching strain of hepatitis C.


Kwiatkowski was fired a few weeks into his temporary job at UPMC in 2008 after a co-worker accused him of swiping a fentanyl syringe from an operating room and sticking it down his pants. Citing a lack of evidence, hospital authorities didn’t call police, and neither the hospital nor the medical staffing agency that placed him in the job informed the national accreditation organization for radiological technicians. Within days, Kwiatkowski was starting a new job at the Baltimore VA Medical Center, where one patient also has since been diagnosed with hepatitis C linked to Kwiatkowski.


Though the VA center initially said it had identified 168 patients who may have been exposed, that number was later lowered, and 68 patients ultimately were tested. Two other Maryland hospitals where Kwiatkowski worked also have completed their testing, with no diagnosed cases of hepatitis C matching Kwiatkowski. But at the fourth, The Johns Hopkins Hospital in Baltimore, four patients have been diagnosed with the strain of disease linked to Kwiatkowski.


About 500 of the 1,567 patients notified by Johns Hopkins have yet to be tested, according to hospital spokeswoman Kim Hoppe. Kwiatkowski had been referred by a staffing agency that assured Johns Hopkins that it had followed a vigorous vetting process, Hoppe said. He worked there for two 13-week stints, from July 2009 to January 2010.


Saint Francis Hospital in Poughkeepsie, N.Y., where Kwiatkowski worked in late 2007 and early 2008, notified and tested 31 patients without finding any linked cases to Kwiatkowski. In Kansas, nearly all of the 416 patients who may have been exposed at Hays Medical Center have been tested and six have been diagnosed with infections linked to the New Hampshire outbreak.


There have been no cases linked to Kwiatkowski in Arizona, where about 300 patients from two hospitals have been asked to get tested and about 280 have done so. Kwiatkowski worked at Maryvale Hospital in Phoenix in 2009 and the Arizona Heart Hospital in 2010. He was fired from the latter job after 10 days after a co-worker found him passed out in a bathroom stall with a stolen fentanyl syringe floating in the toilet.


That incident was reported to police, Kwiatkowski’s staffing agency, a state regulatory board and the national accreditation organization, but the accreditation group dropped its inquiry after learning police hadn’t filed charges.


Days later, Kwiatkowski landed a new job filling in for striking technicians at Temple University Hospital in Philadelphia. That hospital has recommended testing for 312 patients but won’t say how many have followed through or have been diagnosed with hepatitis C. A hospital spokesman referred questions to the city health department, which did not return calls.


Testing also is still under way in the last place Kwiatkowski worked before heading to New Hampshire — Houston Medical Center in Warner Robins, Ga. According to the hospital, fewer than 100 people have yet to be tested, and there haven’t been any cases yet linked to Kwiatkowski.


In New Hampshire, where about 3,300 patients were tested, Kwiatkowski is charged with seven counts of illegally obtaining drugs and seven counts of tampering with a consumer product, though prosecutors have said further charges are possible. Although New Hampshire cannot charge him for possible violations in other states, it can use evidence gathered in those jurisdictions in its trial, U.S. Attorney John Kacavas said. Other states are waiting to see the outcome of New Hampshire’s case before deciding whether to file charges, he said.


“We continue to reach out to other states affected by this matter,” Kacavas said this week. “Other health organizations and departments continue to do their work in their states, but nothing has changed in the sense that our prosecution will go forward. At this point, we are the only prosecution in the country, and we’ll see how it rolls out.”


Health News Headlines – Yahoo! News





Title Post: Hepatitis C tests continue after NH tech’s arrest
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

News Corp publishing loses $2.1bn







News Corporation says its publishing wing incurred a $ 2.1bn (£1.3bn) loss in the last financial year.






Revenues fell 5%, partly as a result of the closure of the News of the World, which it stopped publishing after the phone-hacking scandal broke in the UK.


The company detailed the losses as it formally applied to US regulators the Securities and Exchange Commission to split its business into two.


News Corp plans to separate publishing from its film and TV business.


The publishing arm, which News Corp said had made a profit of $ 678m the year before, will be called New News Corp. It will include book publisher Harper Collins, the Times and the Sun newspapers in the UK, the Wall Street Journal, the New York Post and the Australian.


The more lucrative TV and film business will be the parent company and will be called Fox Group.


It will include the US news channel Fox News and the 20th Century Fox film studio.


‘Adverse trends’


The loss made by the publishing arm included a $ 2.6bn impairment charge, after writedowns of $ 1.3bn for goodwill and $ 1.3bn for other intangible assets, primarily newspaper mastheads and distribution networks.


These impairment charges were largely the result of “adverse trends affecting several businesses”, including a weakening economic environment in Australia and lower predicted revenues from certain businesses.


The charges also reflected the expected sale of certain assets at a value below their carrying value, News Corp said.


The company first announced its plan to split in June, after pressure from shareholders who were concerned about the damage done to the publishing business by the events at the News of the World.


Robert Thomson, who is currently the managing editor of the Wall Street Journal and previously edited the Times, will be head of the new publishing company.


He will receive an annual salary of $ 2m, and a performance-based annual bonus with a target of $ 2m.


Rupert Murdoch will carry on as chairman and chief executive of the parent company, for which his compensation totalled $ 30m in the last year.


His pay will increase “modestly” as he takes on the role of executive chairman of the publishing company.


BBC News – Business





Title Post: News Corp publishing loses $2.1bn
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

SaleSpider Media Gets Ready for 2013






SaleSpider Media had an extremely successful 2012 and looks to bring that success into 2013.


toronto, ON (PRWEB) December 21, 2012






SaleSpider Media had an extremely successful 2012 and looks to bring that success into 2013. Over the past year each of SaleSpider Media’s social networks have growth substantially. SaleSpider.com, North America‘s largest SMB social network, grew by over 500% in 2012. SaleSpider Media’s other properties, HomeOwnersCircle.com and WealthMason.com, each grew by over 2000% in traffic over the same time period.


The substantial growth of SaleSpider Media can be attributed to the company’s digital innovations in the past year, here is a quick snapshot:


SaleSpider Media looks to continue to bring great innovations to our social platforms and grow with our users in the coming year of 2013.


About Sales Spider Media:



SaleSpider Media is a leading internet company with multiple fast-growing, highly-related brands serving loyal consumer and business audiences…our mission is to harness the power of interactivity to make daily life easier and more productive for people all over North America and The World.



SaleSpider Media’s exclusive web properties have millions of unique visitors and opt-in members and are growing by over 90% each quarter. The company has deep reach to in-market buyers in Auto, Travel, Finance, Insurance, Technology, B2B, and many more!



SaleSpider Media works with top Fortune 100 companies and is a leader in…


  • First Party Data Targeting reaching “ready to buy” consumers

  • Reaching Business Decision Makers by company size, industry, title and geography

  • Social Media, multiple platforms including the largest small business social network in North America

To learn more about SaleSpider Media, please see SaleSpiderMedia.com.


PR
Sales Spider Inc.
4162210447
Email Information


Internet News Headlines – Yahoo! News





Title Post: SaleSpider Media Gets Ready for 2013
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

BMG Scores Rights to Nirvana, Tears for Fears Songs






NEW YORK (TheWrap.com) – BMG has acquired the worldwide rights to several music catalogues, a deal that will give it songs from artists including Kurt Cobain, Tears for Fears, The Human League, Iggy Pop, and Take That.


The company announced Friday that it will purchase the rights for the Virgin Music Publishing Companies, Famous UK Music Publishing and selected current songwriters from Sony/ATV and EMI Music Publishing.






Sony Corporation of America and a group of investors acquired EMI Music Publishing in June, and Sony/ATV Music Publishing administers EMI on behalf of the group. It had to sell the catalogues as a condition of the acquisition.


Virgin Publishing’s catalogue includes Kurt Cobain‘s songs for Nirvana, including “Smells Like Teen Spirit,” “Come As You Are” and “About A Girl.”


Other hits include Jim Steinman’s “Total Eclipse Of The Heart,” Lenny Kravitz’ “Are You Gonna Go My Way,” Mark Ronson and Amy Winehouse’s “Back to Black,” and Devo’s “Whip It.”


Other songs include Take That’s greatest hits, including “Patience,” “Shine” and “Greatest Day,” as well as former member Robbie William’s interests in “Angels,” “Rock DJ” and “Let Me Entertain You.”


Also in the catalogue are Tears for Fears‘ “Everybody Rules The World,” Culture Club’s “Karma Chamelon,” OMD’s “Enola Gay,” and Iggy Pop‘s “Lust for Life,” as well as recent hits including Duffy’s “Mercy.”


BMG, the fourth-largest music publishing company, is a three-year-old partnership between Bertelsmann and Kohlberg Kravis Roberts & Co. In May, it announced it had more than one million copyrights under management.


“These catalogues contain some of the most influential and successful songs in popular music,” said BMG CEO Hartwig Masuch. “We are delighted to have won the opportunity to represent the writers of those songs and to demonstrate to them BMG‘s commitment to twenty-first century service. They have my pledge that we will do our very best to deliver for them.”


Music News Headlines – Yahoo! News





Title Post: BMG Scores Rights to Nirvana, Tears for Fears Songs
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Gilead A Strong Buy On New HIV Treatments







Jordo is a member of The Motley Fool Blog Network — entries represent the personal opinions of our bloggers and are not formally edited.






Despite the expiration of some of its HIV patents in 2018, Gilead Sciences’ (NASDAQ: GILD) new HIV treatments will enable the company to extend its HIV-based profitability for the long-term.


Gilead has done well with fixed-dose combination pills Truvada and Atripla combining multiple HIV medications into a single pill. The company has been rewarded with an impressive market share in the HIV treatment market, and is now looking for the same success in the treatment of Hepatitis C. Sofosbuvir, a novel Hepatitis C drug, recently demonstrated promising results in the first of several phase 3 trials, with 78% of patients having an undetectable viral load 12 weeks following treatment.


There are two characteristics of sofosbuvir which make it a potential blockbuster. First, if approved by the FDA, it would be the first all-oral Hepatitis C treatment. Second, it avoids the use of interferon, a component of standard Hepatitis C treatments associated with unfavorable side effects. Half the patients that take interferon typically develop flu-like symptoms, and one-third develop psychiatric complications such as depression. These challenges in the current Hepatitis C treatment regiments have led to approximately one-third of patients discontinuing treatment. As an all-oral, low side-effect medication, sofosbuvir has the potential to sharply reduce this rate of non-compliance and, in doing so, establish itself as the dominant drug in the treatment of Hepatitis C in a market estimated at over $ 20 billion. Sofosbuvir is currently progressing through phase 3 trials.


Drug Pipeline


Gilead has also recently introduced another HIV drug, Stribild, that is poised to become a lead drug choice in HIV treatment. A four-drug combination pill that builds on the success of Gilead’s single-pill model, Stribild has been predicted to become the market leading HIV drug within the next decade. In addition, Gilead produces all of the component drugs within Stribild, and they would avoid the revenue sharing arrangements associated with their previous HIV medications.


Gilead has also ramped up its research into oncology drugs, with several drugs in its pipeline being tested as treatments for colorectal cancer, pancreatic cancer and a specific type of leukemia. In December, Gilead bought YM BioSciences (NYSEMKT: YMI), a Canadian company, for $ 510 million in cash, mainly to get access to the Canadian company’s research into treatments for a bone-marrow disorder. The Canadian company’s lead drug candidate, CYT387, is an orally-administered, once-daily, selective inhibitor of the Janus kinase (JAK) family, specifically JAK1 and JAK2 and combats myelofibrosis, a bone-marrow disease that can lead to anemia and an enlarged spleen. The acquisition provides Gilead with a promising treatment at a reasonable price.


Financials


Total revenues for the third quarter of 2012 increased 14% to $ 2.43 billion, from $ 2.12 billion for the third quarter of the previous year. Net income for the third quarter was $ 675.5 million, or $ 0.85 per diluted share compared to $ 741.1 million or $ 0.95 per diluted share for the third quarter of 2011. Non-GAAP net income for the third quarter of 2012, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $ 788.9 million, or $ 1.00 per diluted share compared to $ 795.2 million, or $ 1.02 per diluted share for the third quarter of 2011.


As of Sept. 30, 2012, Gilead had $ 2.65 billion of cash, cash equivalents and marketable securities compared to $ 9.96 billion as of Dec. 31, 2011. The decrease was due to the acquisition of Pharmasset in the first quarter of 2012. Gilead generated $ 2.49 billion of operating cash flow during the first nine months of 2012 including $ 745.4 million generated in the third quarter of 2012.


Analyst Ratings


Zacks reiterated its neutral rating on Gilead with a price target of $ 78.00. Analysts at Guggenheim reiterated a “buy” rating on Gilead with a price target of $ 87. On Dec. 5, analysts at Oppenheimer reiterated an “outperform” rating on Gilead. On Dec. 4, 2012, Barclays Capital reaffirmed its “overweight” rating on Gilead with a price target of $ 76. On Nov. 30, Gilead had its “overweight” rating affirmed by Piper Jaffray with a price target of $ 85. On Nov. 13, analysts at Stifel Nicolaus raised their price target on Gilead from $ 80 to $ 85 with a “buy” rating. On the same date, Lazard also raised its price target on Gilead from $ 89 to $ 100 with a “buy” rating.


Competition


Gilead’s HCV candidate sofosbuvir, which was added to Gilead’s pipeline through its acquisition of Pharmasset, is now in phase 3 trials. The results put Gilead in the lead in what has become a two-horse race with Abbott Laboratories (ABT) to produce the first treatment for the disease that doesn’t include interferon with its negative side effects. In the case of CYT387 included in the recent YM BioSciences acquisition, potential rivals in the field are Incyte (INCY) and Novartis’ (NVS) JAK inhibitor Jakafi, which the FDA approved last year to combat myelofibrosis. Cell Therapeutics (CTIC) has its own midstage program focusing on the blood disease. 


Bristol-Myers Squibb (NYSE: BMY)is testing sofosbuvir plus their NS5A inhibitor daclatasvir (formerly BMS-790052). Bristol-Myers Squibb had a clinical collaboration with Pharmasset and started this trial before Gilead’s acquisition. It appears, though, that these two competing companies, notably Gilead, are not interested in conducting a phase3 study to evaluate this combination. Bristol-Myers Squibb is also evaluating multiple HCV drug candidates. The acquisition of Zymogenetics in 2010 for $ 885 million brought pegylated interferon lambda while the company acquired INX-189 (now called as BMS-986094) through the acquisition of Inhibitex in 2012 for $ 2.5 billion.


Conclusion


I have every reason to believe that Gilead is going to continue to be highly successful, and I have no hesitation in recommending this stock to investors.


Sexual Health News Headlines – Yahoo! News





Title Post: Gilead A Strong Buy On New HIV Treatments
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

The NRA’s Solution: A Gun in Every School






With characteristic flair, the National Rifle Association held America in suspense for a week on how it would react to the Newtown (Conn.) school massacre and then came out, guns blazing.


Wayne LaPierre, the NRA’s longtime top official, left no doubt during his nationally televised press conference that the pro-gun lobby—pound for pound, the most effective single-issue advocacy group in Washington—will fight fiercely against any new restrictions on the lawful acquisition of guns, magazines, or ammunition.






Whether the group wins or loses the coming debate, it wins (more on that in a moment). First, here are the basics of what LaPierre had to say:


• Setting up schools as “gun-free zones” has been an utter failure. Schools require more security, including a police officer in every school. The NRA will lead a national “school shield” initiative headed by Asa Hutchinson, a former head of the Drug Enforcement Administration, former U.S. congressman, and former federal prosecutor.


• The nation ought to establish a comprehensive database of mentally ill individuals. Those who have been deemed mentally ill, alcoholic, or addicted to drugs are already banned by federal law from acquiring guns. LaPierre called for more thorough record-keeping, a demand made by many of his opponents in the gun-control camp.


• The national media, whom LaPierre repeatedly castigated, bear responsibility for random mass shootings because they provide saturation coverage of events such as the Newtown massacre, and that encourages “copycats.”


• Hollywood and makers of violent video games, which LaPierre called the worst kind of “pornography,” likewise bear responsibility for mass shootings. The entertainment industry, he said, creates an atmosphere in which young people view violence as routine and without consequence.


• Gun owners, however, do not bear responsibility for mass shootings, and more gun regulations are not needed, he said. Instead, he condemned federal prosecutors for pursuing fewer gun-crime cases. There are already 20,000 gun regulations on the books, LaPierre said.


• He accused the media of fomenting “hatred” of gun owners and the NRA. He also alluded to the danger of civic unrest in the event of another disaster similar to Sandy, the devastating storm that recently hit the East Coast. That’s a subtle signal in support of survivalists and others who stock up on armaments out of fear that the government can’t protect them in chaos.


The NRA, as will become apparent in weeks and months to come, has a structural advantage in this conflict with gun-control forces. It does not compromise, because it does not fear losing. By framing the debate as one of gun owners against the rest of society (the media, Hollywood, “political elites”), LaPierre is paving the way for his next fund-raising solicitation. If some new gun-control law gets enacted, that becomes evidence that the vast anti-gun conspiracy only wants more, that President Barack Obama eventually will come for YOUR guns—all of them.


The lobby and the industry whose fortunes it promotes thrive on controversy, observes Richard Feldman, a former NRA organizer and gun trade association executive. “If the NRA wins, it wins,” he says. “If it loses, it wins, too, because then it can raise money on its defeat—and go back and try again.”


A relevant datum that LaPierre did not stress as part of his presentation was that, as the industrialized democracy with the greatest prevalence of gun ownership—300 million firearms in private hands; 47 percent of households possessing one or more guns—the U.S. has the highest gun homicide rate among economically advanced countries.


Businessweek.com — Top News





Title Post: The NRA’s Solution: A Gun in Every School
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Wounded presage health crisis for postwar Syria






ATMEH, Syria (AP) — A baby boy joined the ranks of Syria’s tens of thousands of war wounded when a missile fired by Bashar Assad‘s air force slammed into his family home and shrapnel pierced his skull.


Four-month-old Fahed Darwish suffered brain damage and, like thousands of others seriously hurt in the civil war, he will likely need care well after the fighting is over. That’s something doctors say a post-conflict Syria won’t be able to provide.






Making things worse, there has been a sharp spike in serious injuries since the summer, when the regime began bombing rebel-held areas from the air, and doctors say a majority of the wounded they now treat are civilians.


This week, Fahed was recovering from brain surgery in an intensive care unit, his head bandaged and his body under a heavy blanket, watched over by Mariam, his distraught 22-year-old mother.


She said that after her first-born is discharged from the hospital in Atmeh, a village in an area of relative safety near the Turkish border, they will have to return to their village in a war zone in central Syria.


“We have nowhere else to go,” she said.


Even for those who have escaped direct injury, the civil war is posing a mounting health threat. Half the country’s 88 public hospitals and nearly 200 clinics have been damaged or destroyed, the World Health Organization says, leaving many without access to health care. Diabetics can’t find insulin, kidney patients can’t reach dialysis centers. Towns are running out of water-purifying materials. Many of the hundreds of thousands displaced by the fighting are exposed to the cold in tents or unheated public buildings.


“You are talking about a public health crisis on a grand scale,” said Dr. Abdalmajid Katranji, a hand and wrist surgeon from Lansing, Michigan, who regularly volunteers in Syria.


No one knows just how many people have been injured since the uprising against Assad erupted in March 2011, starting out with peaceful protests that turned into an armed insurgency in response to a violent government crackdown.


More than 43,000 have been killed in the past 21 months, said Rami Abdul-Rahman, head of the Britain-based Syrian Observatory for Human Rights, basing his count on names and details provided by activists in Syria. He said the number of wounded is so large he can only give a rough estimate, of more than 150,000.


Casualties began to rise dramatically at the start of the summer. At the time, the regime, its ground troops stretched thin, began bombing from the air to prevent opposition fighters from gaining more territory.


Seemingly random bombings have razed entire villages and neighborhoods, driving terrified civilians from their homes, with an estimated 3 million Syrians out of the country’s population of 23 million now displaced.


About 10 percent of the wounded suffer serious injuries and many of those will need long-term care and rehabilitation, said Dr. Omar Aswad of the Union of Syrian Medical Relief Organizations, an umbrella for 14 aid groups.


This includes artificial limbs and follow-up surgery. “This is of course not available and will be one of the major (health) problems in the months right after the war,” said Mago Tarzian, emergency director for the Paris-based Doctors Without Borders.


For now, aid groups are struggling to provide even emergency treatment in under-equipped clinics.


The two dozen small hospitals and field clinics in rebel-run areas of Idlib province in the north only have a few Intensive Care Unit beds between them, said Aswad. None has a CT scanner, an important diagnostic tool.


“We need generators, we need medical supplies and the most pressing is medicine,” he said.


The challenge has been compounded by new types of injuries.


The regime has begun dropping incendiary bombs that can cause severe burns, according to the New York-based Human Rights Watch, citing amateur video and witness accounts.


Ole Solvang, a researcher for the group, said he saw remnants of such a bomb on a recent Syria trip. Aswad said doctors in Idlib and nearby Aleppo province reported seeing patients with burns from such weapons.


Doctors and hospitals have also been targeted. Aswad, who fled the city of Idlib in March after regime forces entered it, said five friends in a secret association of anti-regime physicians have been arrested. Hospitals, ambulances and doctors have been attacked, Solvang said, calling it “a worrying trend that makes the medical situation even worse.”


One of the bright spots is a 50-bed emergency care clinic set up six weeks ago in a former elementary school in Atmeh.


Largely funded by a wealthy Syrian expatriate, the Orient clinic, with five ICU beds, handles some of the most serious cases in a radius of some 150 kilometers (90 miles), said its director, orthopedic surgeon Abdel Hamid Dabbak.


In the past, seriously wounded patients had to go to Turkey, risking dangerous delays at the border, he said. Now, once patients are stabilized in Atmeh, they are sent to a sister clinic across the border for follow-up care.


In Orient’s ICU, a 24-year-old rebel fighter was breathing oxygen through a mask. He had been brought in a day earlier, bleeding heavily from stomach wounds and close to death, said Dr. Maen Martini, a volunteer physician from Joliet, Illinois. After surgery, he stabilized and was taken off a respirator. A delayed crossing into Turkey would have killed him, Martini said.


The fighter’s neighbor was little Fahed, whose house had been struck by a missile on Saturday in the village of Kafr Zeita in Hama province. “The roof collapsed on us,” his mother said of the attack. “We ran out … I saw him bleeding from his head, but it was just a small cut.”


The local clinic said the injury was more serious than it seemed and the family rushed to Atmeh, more than 100 kilometers (60 miles) to the north.


Since surgery, Fahed has been nursing and has moved his arms and legs, and the doctor is hoping for a near-complete recovery.


“Clinically, he has improved dramatically,” he said.


Middle East News Headlines – Yahoo! News





Title Post: Wounded presage health crisis for postwar Syria
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Huge Savings With MyBatua Season’s Sale






The online Islamic clothing store MyBatua.com brings more reasons to smile. The Store announces huge discounts and assured gifts on every purchase of women Abayas, kurtis and Jibabs.


(PRWEB) December 21, 2012






MyBatua.com has extended its seasonal sale on Islamic clothing range for a fortnight to appreciate the huge response of buyers. Being one of the most renowned stores for a vibrant range of Islamic clothing range, MyBatua has announced discounts up to 60% on modern, contemporary, fashionable and exclusive Islamic apparel for men and women.


The online store offers a huge collection of Jibabs, kurtis, abayas and Hijabs for customers, with the choice of customization. All the clothing items displayed at the sale are designed to reflect exclusive style statements of customers. Islamic outfits at MyBatua are available with contemporary and very stylish looks. Jilbabs and Abaya at the store are also made from natural fabric and with contemporary texture.


At http://www.mybatua.com visitors may choose from an extensive range of hijabs available in different styles, plain solid colors, fantastic design and attractive ones for joyful events. Like their name they are very simple to put on without any wrapp or Hijab pin. The store is well-known for its best quality beautiful hijabs and Abayas with an inexpensive price tag.


The best part of the season sale at the store is the availability of the finest range of ethnic clothing for a diverse array of women buyers who never compromise on quality and style. The store features a diverse variety of modest Women’s clothing items that range from conventional Abayas to custom Hijabs designed with finest craftsmanship.


Apart from a pretty good collection of regular and Plus sizes of Jibabs, Abayas and Hijab, customers also get an option to customize clothes without any additional cost. With every purchase at http://www.mybatua.com seasonal sale, customers find huge cash discounts and assured gifts to turn their shopping spree rewarding and a never before experience. MyBatua range comes with free shipping and hassle free delivery to the customers worldwide.    


MyBatua a leading online store for clothing and accessories has now become a one stop shopping place for Islamic fashion clothing. It is catering to all needs of online shoppers for Abayas, Jilbabs, Hijabs, Sherwanis and variety of accessories including brooches and unique handbags suitable for all occasions and weddings.


Amrish Goel
Mybatua.com
+918826009522
Email Information


Internet News Headlines – Yahoo! News





Title Post: Huge Savings With MyBatua Season’s Sale
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Putin offers French tax row actor Depardieu a Russian passport






MOSCOW (Reuters) – President Vladimir Putin offered French actor Gerard Depardieu a Russian passport on Thursday, saying he would welcome the 63-year-old celebrity who is embroiled in a bitter tax row with France‘s socialist government.


Weighing into a dispute over a hike in taxes, Putin heaped praise on Depardieu, making the offer of citizenship in response to a question during his annual televised press conference.






“If Gerard really wants to have either a residency permit in Russia or a Russian passport, we will assume that this matter is settled and settled positively,” Putin said.


French daily Le Monde reported on Tuesday that Depardieu had told his close friends he was considering three options to escape France’s new tax regime: moving to Belgium, where he owns a home, relocating to Montenegro, where he has a business, or fleeing to Russia.


“Putin has already sent me a passport,” Le Monde quoted the actor as jokingly saying.


Depardieu is well-known in Russia where he has appeared in many advertising campaigns, and in 2012 he was one of several Western celebrities invited to celebrate the birthday of Ramzan Kadyrov, Chechnya’s Kremlin-backed leader.


He also worked in Russia last year on a film about the life and times of the eccentric Russian monk Grigory Rasputin.


He has already inquired about how to obtain Belgian residency rights and said he plans to hand in his French passport and social security card.


In what has become an ugly public dispute, France’s Prime Minister Jean-Marc Ayrault criticized Depardieu’s announcement as “pathetic” and unpatriotic. The actor hit back, accusing France of punishing success and talent.


But Putin said he thought the feud was the result of a “misunderstanding”.


The 60-year-old former KGB spy said he was very friendly with Depardieu, saying he thought the actor considered himself a Frenchman who loved the culture and history of his homeland.


Belgian residents do not pay a wealth tax, which in France is now levied on those with assets over 1.3 million euros ($ 1.7 million). Nor do they pay capital gains tax on share sales.


Hollande is also pressing ahead with plans to impose a 75-percent super tax on income over 1 million euros.


Russia has a flat income tax rate of 13 percent.


(Reporting by Alexei Anishchuk; Additional reporting by John Irish in Paris; Writing by Gabriela Baczynska; Editing by Alissa de Carbonnel and Andrew Osborn)


Celebrity News Headlines – Yahoo! News





Title Post: Putin offers French tax row actor Depardieu a Russian passport
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents






Landmark clinical trial begins for rapid DNA testing and personalized anti-blood clotting drugs.


Ottawa, Ontario (PRWEB) December 20, 2012






Spartan Bioscience today announced the start of a 5,945-patient study of personalized medicine for cardiac stent patients. The study is sponsored by the Center for Individualized Medicine at Mayo Clinic and is entitled “Tailored Antiplatelet Initiation to Lessen Outcomes due to Clopidogrel Resistance after Percutaneous Coronary Intervention (TAILOR-PCI).”


This clinical trial will evaluate whether genotyping of cardiac stent patients at the time of angioplasty can help improve patient outcomes by informing providers about drug selection of either Brilinta® (ticagrelor) or Plavix® (clopidogrel). These antiplatelet drugs are prescribed after surgery to reduce clotting complications, such as heart attacks, strokes, and cardiovascular deaths. The drugs are thought to work differently in patients with specific variations in the CYP2C19 gene, and the Spartan RX CYP2C19 rapid DNA testing system will be used to identify these variations in some patients of the TAILOR-PCI study. The study will enroll patients over a 22-month period at 9 hospitals in Canada and the United States.


The principal investigator of the TAILOR-PCI study is Naveen Pereira, M.D., a Mayo Clinic cardiologist. Chiranjit Rihal, M.D., chairman of the Division of Cardiovascular Diseases at Mayo Clinic in Rochester, Minnesota, serves as chairman of the TAILOR-PCI steering committee. The Mayo Clinic sites are Rochester; Jacksonville, Florida; Phoenix, Arizona; and the Mayo Clinic Health Systems in La Crosse, Wisconsin; and Mankato, Minnesota. Canadian sites participating in this study are St. Michael’s Hospital, Toronto General Hospital, Sunnybrook Hospital, and the University of Ottawa Heart Institute.


“We are excited to work with Mayo Clinic on this landmark clinical trial,” said Paul Lem, M.D., CEO of Spartan Bioscience. “Rapid DNA testing means doctors and patients do not have to wait days or weeks for results from a central lab.”


About the Spartan RX CYP2C19



The Spartan RX CYP2C19 is the first point-of-care DNA test in medicine.(1) It identifies carriers of certain CYP2C19 genetic mutations in 1 hour. These mutations are carried by approximately 30 percent of the world’s population.(2) Genetic carriers who receive Plavix® following a cardiac stent insertion to open clogged arteries have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) Currently, genetic testing is performed in central labs and it takes up to seven days to get a test result back. A rapid test is needed because most of the complications for CYP2C19 carriers occur in the first 24 to 48 hours.(3,4) In March 2010, the FDA issued a warning for Plavix regarding CYP2C19 poor metabolizers. The Spartan RX CYP2C19 has CE IVD Mark regulatory approval for Europe and other countries recognizing the CE IVD Mark. Spartan Bioscience is working towards FDA 510(k) clearance in the United States. For more information, please visit our website at: http://www.spartanbio.com/products/spartan-rx


About Spartan Bioscience



Spartan Bioscience is the leader in point-of-care DNA testing. The Spartan RX is the first complete sample-to-result, point-of-care DNA testing system in medicine. It is a fully integrated DNA collection, extraction and analysis platform, with an intuitive interface that is easy to operate—no laboratory training required. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.


The Spartan logo is a registered trademark of Spartan Bioscience Inc.



Brilinta is a registered trademark of AstraZeneca.



Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.


1. Roberts JD et al. (2012). Lancet. 379: 1705–1711.



2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–111.



3. Mega JL et al. (2009). N Engl J Med. 360:354–362.



4. Wiviott SD et al. (2007). N Engl J Med. 357:2001–2015.


Paul Lem, M.D.
Spartan Bioscience Inc.
+1 (613) 228-7756 735
Email Information


Medications/Drugs News Headlines – Yahoo! News





Title Post: Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..